<DOC>
	<DOCNO>NCT00422396</DOCNO>
	<brief_summary>This randomize placebo control clinical trial design investigate effect micronized fenofibrate fast postprandial lipoprotein , oxidize fatty acid lipoprotein , inflammatory mediator thrombotic factor among hypertriglyceridemic individual two characteristic metabolic syndrome .</brief_summary>
	<brief_title>Effects Micronized Fenofibrate Fasting Postprandial Lipoproteins , Inflammatory Mediators Thrombosis</brief_title>
	<detailed_description>The aim study determine effect micronized fenofibrate ( 160 mg/daily ) : 1 . Fasting postprandial lipid lipoproteins standarized test meal . 2 . Fasting postprandial oxidize fatty acid oxidize low density lipoprotein standarized test meal . 3 . Fasting postprandial inflammatory mediator standarized test meal . 4 . Fasting postprandial lipopolysaccharide-stimulated cytokine production standarized test meal . 5 . Fasting postprandial marker hemostasis , fibrinolysis blood viscosity standarized test meal .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>1. male postmenopausal females 18 year age fast triglyceride great equal 1.7 mmol/L &lt; 6.9 mmol/L 2. two follow Adult Treatment Panel III ( 1 ) criterion metabolic syndrome : abdominal obesity ( waist circumference &gt; 89 cm female &gt; 102 cm male ) ; low highdensity lipoprotein cholesterol ( HDLC ) ( &lt; 1.3 mmol/L woman &lt; 1.0 mmol/L men ) ; hypertension ( systolic blood pressure &gt; 130 diastolic blood pressure &gt; 85 mm Hg ) current drug therapy hypertension ; impaired fasting glucose ( 6.1 mmol/L 7.0 mmol/L ) . 1. include type 1 2 diabetes 2 . Body mass index &gt; 40 kg/m2 3 . Use lipidlowering therapy 4 . Oral hypoglycemic therapy 5 . Insulin 6 . Aspirin &gt; 81 mg daily 7 . Regular use nonsteroidal antiinflammatory agent cyclooxygenase2 inhibitor , corticosteroid ( oral inhale ) , antioxidant ( include multivitamin ) , herbal fiber supplement recent change type formulation hormone replacement therapy ( last 6 month ) 8 . Alcohol intake &gt; 3 drink per day 9 . Untreated hypothyroidism recent change ( within 2 month ) thyroid replacement therapy 10 . Cigarette smoking ( current within last 6 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypertrigliceridemia</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>Fenofibrate</keyword>
	<keyword>Lipoproteins</keyword>
	<keyword>Cytokines</keyword>
</DOC>